Loading...

Cardiex Ltd
ASX:CDX

Watchlist Manager
Cardiex Ltd Logo
Cardiex Ltd
ASX:CDX
Watchlist
Price: 0.31 AUD Market Closed
Updated: Dec 8, 2022

Intrinsic Value

CDX's intrinsic value estimate is unreliable because it is based only on its relative value.

The intrinsic value of one CDX stock under the Base Case scenario is 0.24 AUD. Compared to the current market price of 0.31 AUD, Cardiex Ltd is Overvalued by 23%.

The Intrinsic Value is calculated as the average of the two valuation methods:

CDX Intrinsic Value
Base Case
0.24 AUD
Overvaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

CDX Profitability Score
Profitability Due Diligence

Cardiex Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
19/100
Profitability
Score

Cardiex Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

CDX Solvency Score
Solvency Due Diligence

Cardiex Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Low Altman Z-Score
Short-Term Liabilities
Positive Net Debt
Long-Term Liabilities
48/100
Solvency
Score

Cardiex Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
78%
Gross Margin
-258%
Operating Margin
-262%
Net Margin
-213%
FCF Margin
-154%
ROE
-145%
ROIC
Other

CDX Capital Structure
Cardiex Ltd

Market Capitalization 39.2M AUD
Total Debt 1.9M AUD
Minority Interest 0 AUD
Preferred Equity 0 AUD
Cash and Equivalents 1.5M AUD
Short-Term Investments 0 AUD
Enterprise Value 39.7M AUD

Wall St
Price Targets

CDX Price Targets Summary
Cardiex Ltd

There are no price targets for CDX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

CDX Competitors
Cardiex Ltd

CDX Suppliers & Customers
Cardiex Ltd

Cardiex Ltd has 2 key suppliers from 2 countries and 2 industries. The majority of these suppliers are located in United Kingdom, with the largest number of suppliers in the Electrical Equipment industry.

Cardiex Ltd has 7 key customers from 5 countries and 4 industries. The majority of these customers are located in United Kingdom, with the largest number of customers in the Pharmaceuticals industry.

Shareholder Return

CDX Price
Cardiex Ltd

1M 1M
-3%
6M 6M
-17%
1Y 1Y
-40%
3Y 3Y
+11%
5Y 5Y
+6%
Annual Price Range
0.31
52w Low
0.27
52w High
0.72
Price Metrics
Average Annual Return 31.01%
Standard Deviation of Annual Returns 64.36%
Max Drawdown -78%
Shares Statistics
Market Capitalization 39.2M AUD
Shares Outstanding 126 531 815
Percentage of Shares Shorted
N/A

Company Profile

Cardiex Ltd

Country

Australia

Industry

Health Care

Market Cap

39.2M AUD

Dividend Yield

0%

Description

CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.

Contact

NEW SOUTH WALES
Sydney
Suite 303, 15 Lime Street
+61298748761.0
https://cardiex.com/

IPO

2005-11-09

Employees

-

Officers

Co-Founder & Exec. Chairman
Mr. Niall Charles Edgar Cairns ACA, B.Ec, FAICD
Co-Founder, CEO, MD & Exec. Director
Mr. Craig R. Cooper BEC, L.L.B.
CFO, Joint Company Sec. & Exec. Director
Mr. Jarrod Travers White B.Bus, C.A., CA, CTA
Operations Director
Steve Braaten
Accounts Mang.
Carol Targos
Chief Science & Research Officer
Ahmad Qasem
Show More
Global Head of Marketing & Communications
Mr. Antony Sloan
VP of Corp. & Bus. Devel.
Mr. ZiHan Lin
Director of Sales
Ric Ruffhead
Exec. VP & Head of Global Sales for AtCor Medical Division
Mr. Douglas T. Kurschinski
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one CDX stock?

The intrinsic value of one CDX stock under the Base Case scenario is 0.24 AUD.

Is CDX stock undervalued or overvalued?

Compared to the current market price of 0.31 AUD, Cardiex Ltd is Overvalued by 23%.